We are live on ! Find out more
KNTE

Kinnate Biopharma Inc. Common Stock
KNTE

Delisted

KNTE was delisted on the 2nd of April, 2024.

Back to rankings

55 hedge funds and large institutions have $1.43B invested in Kinnate Biopharma Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 55 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
55
Holders Change
+55
Holders Change %
–
% of All Funds
0.97%
Holding in Top 10
6
Holding in Top 10 Change
+6
Holding in Top 10 Change %
% of All Funds
0.11%
New
55
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management IV
California
+$388M
2
O
OrbiMed
New York
+$154M
3
RCM
RA Capital Management
Massachusetts
+$144M
4
VVA
Vida Ventures Advisors
Massachusetts
+$110M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$98.3M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
26
Invesco
Georgia
$6.66M +$6.72M +167,383 New
AG
27
Artal Group
Luxembourg
$4.97M +$5.02M +125,000 New
Victory Capital Management
28
Victory Capital Management
Texas
$4.25M +$4.28M +106,750 New
Millennium Management
29
Millennium Management
New York
$3.57M +$3.6M +89,796 New
DCM
30
DAFNA Capital Management
California
$2.71M +$2.73M +68,121 New
Goldman Sachs
31
Goldman Sachs
New York
$2.4M +$2.42M +60,286 New
Tudor Investment Corp
32
Tudor Investment Corp
Connecticut
$1.61M +$1.62M +40,373 New
UBS Group
33
UBS Group
Switzerland
$1.59M +$1.6M +39,953 New
TD Asset Management
34
TD Asset Management
Ontario, Canada
$1.52M +$1.54M +38,286 New
Geode Capital Management
35
Geode Capital Management
Massachusetts
$1.17M +$1.18M +29,480 New
PCM
36
Pinz Capital Management
New York
$1.02M +$1.03M +25,600 New
EC
37
EcoR1 Capital
California
$995K +$1M +25,000 New
Norges Bank
38
Norges Bank
Norway
$995K +$1M +25,000 New
ECM
39
ExodusPoint Capital Management
New York
$835K +$842K +20,994 New
Citigroup
40
Citigroup
New York
$607K +$612K +15,263 New
Ensign Peak Advisors
41
Ensign Peak Advisors
Utah
$597K +$602K +15,000 New
SG Americas Securities
42
SG Americas Securities
New York
$533K +$538K +13,400 New
TEE
43
Tibra Equities Europe
United Kingdom
$533K +$538K +13,400 New
MFS
44
Mirabella Financial Services
United Kingdom
$412K +$416K +10,360 New
American Century Companies
45
American Century Companies
Missouri
$284K +$286K +7,135 New
Qube Research & Technologies (QRT)
46
Qube Research & Technologies (QRT)
United Kingdom
$242K +$244K +6,072 New
Jane Street
47
Jane Street
New York
$241K +$243K +6,049 New
MS
48
Maven Securities
Jersey
$237K +$239K +5,952 New
Wellington Management Group
49
Wellington Management Group
Massachusetts
$227K +$229K +5,698 New
HF
50
HRT Financial
New York
$223K +$225K +5,617 New
1
2
3

KNTE Hedge Fund Activity: Q4 2020 in Review

55 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q4 2020, worth a combined $1.43B.

Buyers outnumbered sellers: 55 funds opened new KNTE positions and 0 closed out — a net gain of 55 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Foresite Capital Management IV, opening a new position worth an estimated $388M.

  • 55 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q4 2020, up from 0 in Q3 2020.
  • Funds reported $1.43B of Kinnate Biopharma Inc. Common Stock stock for Q4 2020.
  • 55 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q4 2020 and 0 closed out, a net change of +55 holders.
  • The largest Kinnate Biopharma Inc. Common Stock buyer in Q4 2020 was Foresite Capital Management IV, an estimated $388M added.

Based on aggregated 13F filings for Q4 2020.